Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, Hypercon™, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally.
Formulating the Future of Biologics™. www.Elektrofi.com
Company Details
- Employees
- 98
- Founded
- -
- Address
- 25 Drydock Ave, Floor 2,united States
- in****@****ofi.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- elektrofi.com
- HQ
- Boston, Massachusetts
Elektrofi Questions
Elektrofi's website is elektrofi.com
Elektrofi's LinkedIn profile is https://www.linkedin.com/company/elektrofi
Elektrofi has
98 employees.
View email and phone details for 98
employees at Elektrofi.
Elektrofi's industry is
Biotechnology Research
Elektrofi's top competitors are
Lapix Therapeutics,
Sera Medicines, Llc,
Alnylam Pharmaceuticals,
Verve Therapeutics,
Moderna,
Tessera Therapeutics,
Mytide Therapeutics,
Eli Lilly And Company,
Sanofi,
Vertex Pharmaceuticals.
Elektrofi's support email address is info@elektrofi.com
Elektrofi's categories are Biotechnology Research
Elektrofi's founding year is 2016
